RCM
JSPR icon

Rivernorth Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Rivernorth Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,141
Closed -$1.31M – 586
2021
Q2 		$1.31M Hold
13,141
– – 0.07% 193
2021
Q1 		$1.3M Hold
13,141
– – 0.08% 175
2020
Q4 		$1.31M Sell
13,141
-6,201
-32% -$617K 0.08% 164
2020
Q3 		$1.92M Buy
+19,342
New +$1.93M 0.12% 152

Other funds holding JSPR

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPARFS
Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Rivernorth Capital Management's JSPR Position: Q3 2021 in Review

Rivernorth Capital Management sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 13,141 shares — an estimated $1.31M sold.

Rivernorth Capital Management first reported a position in JSPR in Q3 2020 and held it in 4 quarters. The position peaked at $1.92M in Q3 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

  • Rivernorth Capital Management reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Rivernorth Capital Management sold 13,141 Jasper Therapeutics shares in Q3 2021, an estimated $1.31M.
  • Rivernorth Capital Management first reported a position in Jasper Therapeutics in Q3 2020 and held it in 4 quarters.
  • Rivernorth Capital Management's Jasper Therapeutics position peaked at $1.92M in Q3 2020.
  • 10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Rivernorth Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.